Alzheimer's Disease: Learning the Lessons Of The Past To Prepare For The Future

.leftNav1 { width: 750px; }.midNav { display: none; } Alzheimer's disease is the most common cause of dementia among the elderly, accounting for between 60% and 80% of cases in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Despite decades of heavy investment in research, effective treatments for this cognitive disease are still few and AD has become a graveyard for a lot of promising drugs and billions of R&D dollars.

No approved treatment has been able to halt the underlying disease processes in the brain in AD patients, and no new treatment has been approved at all in the last decade in this field.Research, and the development of new therapies, has been fraught by a large number of late-stage, high-profile failures in recent years and a vast number of asset suspensions in the earlier stages of development, too.

According to data held by BioMedTracker (BMT), the AD pipeline in the US includes 47 Phase I products that have...

Welcome to Scrip

Create an account to read this article

More from Alimentary/Metabolic

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By 

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By 

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

More from Therapy Areas

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.